Atomoxetine/Attention Deficit/ Hyperactive Disorder (ADHD)/Substance Use Disorder (SUD)in a Residential Treatment Facility
Status:
Completed
Trial end date:
2008-04-01
Target enrollment:
Participant gender:
Summary
Although Attention Deficit/ Hyperactive Disorder (ADHD) is a common comorbidity in
individuals diagnosed with Substance Use Disorder (SUD), little data currently exists on the
utility of screening tools in large samples of adult patients with SUD in inpatient
treatment. This was a 10-week, 2-phase, open label trial of atomoxetine for ADHD in adult
patients being treated for a co-morbid SUD in a residential treatment facility (RTF). The
primary objective of the study was to assess the efficacy of atomoxetine in adults with an
SUD and ADHD. Secondary objects included assessment of the co-morbidity of ADHD and the
safety and tolerability of atomoxetine in this population.
Phase:
N/A
Details
Lead Sponsor:
New York University School of Medicine NYU Langone Health